JP2022521635A5 - - Google Patents
Info
- Publication number
- JP2022521635A5 JP2022521635A5 JP2021550035A JP2021550035A JP2022521635A5 JP 2022521635 A5 JP2022521635 A5 JP 2022521635A5 JP 2021550035 A JP2021550035 A JP 2021550035A JP 2021550035 A JP2021550035 A JP 2021550035A JP 2022521635 A5 JP2022521635 A5 JP 2022521635A5
- Authority
- JP
- Japan
- Prior art keywords
- fibrous
- disease
- pharmaceutically acceptable
- acceptable salt
- condition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024146122A JP2024174909A (ja) | 2019-02-27 | 2024-08-28 | Ｓｒｃキナーゼ阻害剤を使用して線維性疾患若しくは線維性状態又は間質性肺疾患を処置する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962811009P | 2019-02-27 | 2019-02-27 | |
| US62/811,009 | 2019-02-27 | ||
| PCT/IB2020/051642 WO2020174420A1 (en) | 2019-02-27 | 2020-02-26 | Method of treating a fibrotic disease or condition or of an interstitial lung disease using a src kinase inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024146122A Division JP2024174909A (ja) | 2019-02-27 | 2024-08-28 | Ｓｒｃキナーゼ阻害剤を使用して線維性疾患若しくは線維性状態又は間質性肺疾患を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022521635A JP2022521635A (ja) | 2022-04-11 |
| JP2022521635A5 true JP2022521635A5 (https=) | 2023-03-06 |
| JP7547356B2 JP7547356B2 (ja) | 2024-09-09 |
Family
ID=69784492
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021550035A Active JP7547356B2 (ja) | 2019-02-27 | 2020-02-26 | Ｓｒｃキナーゼ阻害剤を使用して線維性疾患若しくは線維性状態又は間質性肺疾患を処置する方法 |
| JP2024146122A Pending JP2024174909A (ja) | 2019-02-27 | 2024-08-28 | Ｓｒｃキナーゼ阻害剤を使用して線維性疾患若しくは線維性状態又は間質性肺疾患を処置する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024146122A Pending JP2024174909A (ja) | 2019-02-27 | 2024-08-28 | Ｓｒｃキナーゼ阻害剤を使用して線維性疾患若しくは線維性状態又は間質性肺疾患を処置する方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220117966A1 (https=) |
| EP (1) | EP3930715B1 (https=) |
| JP (2) | JP7547356B2 (https=) |
| CN (1) | CN113811296B (https=) |
| DK (1) | DK3930715T3 (https=) |
| ES (1) | ES2994095T3 (https=) |
| FI (1) | FI3930715T3 (https=) |
| HU (1) | HUE067967T2 (https=) |
| MA (1) | MA55076A (https=) |
| PT (1) | PT3930715T (https=) |
| TW (1) | TWI836022B (https=) |
| WO (1) | WO2020174420A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112674031B (zh) * | 2020-12-03 | 2021-11-30 | 同济大学 | 新型冠状病毒感染的啮齿动物模型的构建方法和用途 |
| US20250161250A1 (en) * | 2022-02-28 | 2025-05-22 | Nuformix Technologies Limited | Compositions and methods for treatment of idiopathic pulmonary fibrosis |
| CN117618436A (zh) * | 2022-08-25 | 2024-03-01 | 广州再极医药科技有限公司 | 一种稠环嘧啶类化合物的用途 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73993C2 (uk) | 2000-06-06 | 2005-10-17 | Астразенека Аб | Хіназолінові похідні для лікування пухлин та фармацевтична композиція |
| GB0427697D0 (en) | 2004-12-17 | 2005-01-19 | Astrazeneca Ab | Chemical process |
| US9844528B2 (en) * | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| CN102675282B (zh) * | 2011-03-15 | 2014-12-24 | 广东东阳光药业有限公司 | 取代的喹啉化合物及其使用方法和用途 |
| US20130336889A1 (en) * | 2012-06-14 | 2013-12-19 | National Taiwan University | Nanoparticle and method for detecting or treating a tumor using the same |
| CN105294682B (zh) * | 2014-07-26 | 2017-07-07 | 广东东阳光药业有限公司 | Cdk类小分子抑制剂的化合物及其用途 |
| EP4653015A3 (en) * | 2015-01-26 | 2025-12-31 | Yale University | COMPOSITIONS AND METHODS OF USE OF TYROSINE KINASE INHIBITORS |
| EP3277282B1 (en) * | 2015-04-01 | 2022-10-12 | Istanbul Universitesi Rektorlugu | Dasatinib for use in the treatment, regression or decelerating the progress of fibrotic lung diseases |
| GB201514760D0 (en) * | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
| JP6905662B2 (ja) * | 2015-11-14 | 2021-07-21 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． | 置換キノリン化合物の結晶形およびその医薬組成物 |
| EP3228630A1 (en) * | 2016-04-07 | 2017-10-11 | IMBA-Institut für Molekulare Biotechnologie GmbH | Combination of an apelin antagonist and an angiogenesis inhibitor for the treatment of cancer |
| WO2018026441A1 (en) * | 2016-08-01 | 2018-02-08 | The Regents Of The University Of California | Methods for preventing or treating fibrotic diseases |
| WO2018046876A1 (en) * | 2016-09-06 | 2018-03-15 | The University Of Birmingham | Treatment of chronic inflammatory disease |
| CN106692150B (zh) * | 2016-12-21 | 2019-08-20 | 中国人民解放军第三〇二医院 | 尼达尼布在制备预防和治疗肝纤维化与肝硬化的药物中的用途 |
| EP3964214A1 (en) * | 2020-09-02 | 2022-03-09 | Fraunhofer Gesellschaft zur Förderung der angewandten Forschung e.V. | Modulators of airway basal cells for the treatment or prevention of lung diseases |
-
2020
- 2020-02-26 EP EP20710607.1A patent/EP3930715B1/en active Active
- 2020-02-26 ES ES20710607T patent/ES2994095T3/es active Active
- 2020-02-26 CN CN202080016378.4A patent/CN113811296B/zh active Active
- 2020-02-26 WO PCT/IB2020/051642 patent/WO2020174420A1/en not_active Ceased
- 2020-02-26 JP JP2021550035A patent/JP7547356B2/ja active Active
- 2020-02-26 DK DK20710607.1T patent/DK3930715T3/da active
- 2020-02-26 PT PT207106071T patent/PT3930715T/pt unknown
- 2020-02-26 MA MA055076A patent/MA55076A/fr unknown
- 2020-02-26 HU HUE20710607A patent/HUE067967T2/hu unknown
- 2020-02-26 FI FIEP20710607.1T patent/FI3930715T3/fi active
- 2020-02-26 US US17/434,036 patent/US20220117966A1/en active Pending
- 2020-02-27 TW TW109106616A patent/TWI836022B/zh active
-
2024
- 2024-08-28 JP JP2024146122A patent/JP2024174909A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gaudet et al. | The APPROACH study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS) | |
| JP6244497B1 (ja) | 選択的ｓ１ｐ１レセプターアゴニストの投与法 | |
| JP2015129177A (ja) | 肺深部へのトレプロスチニルの肺送達 | |
| Stass et al. | Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study | |
| JP6208235B2 (ja) | 多発性硬化症治療のためのビオチンの使用 | |
| JP2007302657A (ja) | 痙症の兆候および症候の緩和方法 | |
| JP2022521635A5 (https=) | ||
| KR102766876B1 (ko) | 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물 | |
| EA028060B1 (ru) | Комбинированная терапия бокового амиотрофического склероза | |
| EP2341900B1 (en) | A medicinal product and treatment | |
| EP0642349A1 (de) | Anwendung von urodilatin bei lungen- und bronchialerkrankungen | |
| Molimard et al. | Comparison between formoterol 12 μ g bid and on-demand salbutamol in moderate persistent asthma | |
| HRP20251043T1 (hr) | Novi oralni farmaceutski pripravak i režim doziranja za terapiju progresivnih fibrozirajućih intersticijskih bolesti pluća | |
| WO2020175817A1 (ko) | 섬유증의 예방, 개선 또는 치료용 조성물 | |
| JP2024539476A5 (https=) | ||
| JP7399502B2 (ja) | びらん性変形性手関節症の治療のためのモンテルカスト | |
| JP2021075470A (ja) | 肺線維症の予防または治療のための医薬 | |
| Thirunavukarasu et al. | The Administration of Levodopa in a Patient With Parkinson’s Disease Using a Novel Maxillofacial Route: A First-in-Human Report | |
| TWI922768B (zh) | 包含cdk4抑制劑之用於治療癌症之方法及給藥方案 | |
| US12508272B2 (en) | Long-acting liposomal composition for treatment of pain in articular disorders | |
| AU2010322066A1 (en) | Treatment of acute exacerbation of asthma and reduction of likelihood of hospitalization of patients suffering therefrom | |
| WO2026040961A1 (zh) | pUDK-HGF注射液的用途 | |
| WO2025017193A1 (en) | Methods of treating cardiomyopathy induced by metabolic inflexibility | |
| KR101516452B1 (ko) | 관동맥의 묘출능 개선제 | |
| Nicholls et al. | CARAT: will infusing a pre-beta high-density lipoprotein mimetic (CER-001) regress coronary atherosclerosis? |